Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine acetate for prevention of post-stroke epilepsy in high-risk adults
2018-002747-29Phase 2Completed
- Sponsor
- BIAL
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in epilepsy comparing Eslicarbazepine acetate with Placebo (2 arms). Primary endpoint: First unprovoked seizure within 6 months. Started Jan 2019; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2018-002747-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002747-29.